Opportunity
Federal Register #2026-22339
NHLBI patent-license opportunity for catheter-based intramyocardial ablation technology
Buyer
National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services
Posted
November 02, 2026
Respond By
December 02, 2026
Identifier
2026-22339
NAICS
334510
The National Heart, Lung, and Blood Institute is considering an exclusive patent license for technologies targeting ventricular arrhythmia treatment.
Description
The National Heart, Lung and Blood Institute (NHLBI) is contemplating an exclusive, royalty-bearing patent license to AntaraCore Systems, Inc. for inventions in two patent estates. The license may cover a worldwide territory and a field of use limited to catheter-based intramyocardial ablation for treating ventricular arrhythmia in a human. The inventions include a catheter-based system for accessing and ablating hard-to-reach tissue within the ventricular wall, and a pacing system intended to improve cardiac resynchronization therapy. Written comments and license applications received by NHLBI by December 2, 2026, will be considered.